Join
Live feed
·
PRReleasevia Quantisnow
Zai Lab Limited logo

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
ZLAB· Zai Lab Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZLAB (Zai Lab Limited) and more on Quantisnow.